



Cochrane
Library

Cochrane Database of Systematic Reviews

Glucocorticosteroids for people with alcoholic hepatitis (Protocol)

Pavlov CS, Tsochatzis E, Casazza G, Nikolova D, Volcek E, Gluud C

Pavlov CS, Tsochatzis E, Casazza G, Nikolova D, Volcek E, Gluud C.
Glucocorticosteroids for people with alcoholic hepatitis.
Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.: CD001511.
DOI: 10.1002/14651858.CD001511.pub2.

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
BACKGROUND	1
OBJECTIVES	2
METHODS	3
ACKNOWLEDGEMENTS	8
REFERENCES	8
APPENDICES	12
WHAT'S NEW	13
CONTRIBUTIONS OF AUTHORS	13
DECLARATIONS OF INTEREST	14
SOURCES OF SUPPORT	14
NOTES	14

[Intervention Protocol]

Glucocorticosteroids for people with alcoholic hepatitis

Chavdar S Pavlov^{1,2}, Emmanuel Tsochatzis³, Giovanni Casazza^{1,4}, Dimitrinka Nikolova¹, Edvard Volcek⁵, Christian Gluud¹

¹The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ²Clinic of Internal Diseases Propedeutics, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation. ³Sheila Sherlock Liver Centre, Royal Free Hospital and the UCL Institute of Liver and Digestive Health, London, UK. ⁴Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di Milano, Milan, Italy. ⁵Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth, UK

Contact address: Chavdar S Pavlov, The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. chpavlov@mail.ru.

Editorial group: Cochrane Hepato-Biliary Group.

Publication status and date: Amended to reflect a change in scope (see 'What's new'), published in Issue 6, 2016.

Citation: Pavlov CS, Tsochatzis E, Casazza G, Nikolova D, Volcek E, Gluud C. Glucocorticosteroids for people with alcoholic hepatitis. *Cochrane Database of Systematic Reviews* 2016, Issue 6. Art. No.: CD001511. DOI: 10.1002/14651858.CD001511.pub2.

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis.

BACKGROUND

Description of the condition

The term 'alcoholic hepatitis' was used for the first time in a paper by Beckett and colleagues in 1961 (Beckett 1961), but clinical jaundice after excessive ethanol consumption was reported in the literature long before that (Gerber 1973). Most probably, these reports represented people with alcoholic hepatitis (Mendenhall 1984; Jensen 1994).

Alcoholic hepatitis is a serious form of alcoholic liver disease (injury of the liver due to excessive alcohol consumption) (WHO 2010). Alcoholic hepatitis is synonymous with alcoholic steatohepatitis (Stickel 2013).

The first stage of liver damage in alcoholic hepatitis is usually reversible if people abstain from drinking, but the risk of progression to fibrosis and cirrhosis increases with resumed drinking (Ellis

2012). The accumulation of fat in the hepatocytes causes disruption of the mitochondrial beta-oxidation of fatty acids, accumulation of lipotoxic metabolites, and release of reactive oxygen species (Lieber 1999; Wu 1999; Petrasek 2013). Lipotoxic metabolites and reactive oxygen species lead to cell death and liver inflammation (Wu 1999; Petrasek 2013). Alcoholic hepatitis can be asymptomatic or symptomatic, and the risk of whether or not cirrhosis will develop in a person varies (WHO 2013). Alcoholic hepatitis is a histological form of alcoholic liver disease, characterised by steatosis (the earliest stage of alcoholic liver damage) and necroinflammation (EASL 2012). Only 10% to 35% of heavy drinkers (defined as consumption of more than 60 g to 80 g of alcohol per day in men and more than 20 g of alcohol per day in women), with evidence of fatty liver, are expected to develop hepatitis. With time, alcoholic hepatitis causes liver fibrosis, liver cirrhosis, and primary liver cancer (hepatocellular carcinoma) (WHO 2013). Severe alcoholic hepatitis may be characterised by clinically clear

signs of jaundice, coagulopathy, liver decompensation with ascites, portal hypertension, variceal bleeding, hepatorenal syndrome, hepatic encephalopathy, systemic inflammatory response syndrome, or sepsis (Becker 1996; EASL 2012). Typically, alcoholic hepatitis presents in people aged between 40 and 50 years. Among the risk factors of developing severe alcoholic hepatitis are female sex, Hispanic ethnicity, various types of alcohol, binge drinking, poor nutrition, and obesity (WHO 2010). Several composite prognostic scores exist to distinguish people with poor prognosis from people who can become abstinent, instituting supportive care, until recovery is achieved. These scores, designed to predict mortality, include the Maddrey's discriminant function (Maddrey 1978); the model of end-stage liver disease (MELD) score (Dunn 2005); the Glasgow alcoholic hepatitis score (Forrest 2005); and the age, bilirubin, international normalised ratio, creatinine (ABIC) score (Dominguez 2008).

The Maddrey's discriminant function is the most frequently used score in severe alcoholic hepatitis to identify people in potential need of glucocorticosteroids. The one-month survival of people with alcoholic hepatitis and with Maddrey's score higher than 32 varies between 50% and 65% (Carithers 1989; Phillips 2006). The Lille Model is the only validated model so far to assess glucocorticosteroid response and is highly predictive of death at six months (P value < 0.000001) in people with severe alcoholic hepatitis (Louvet 2007) (www.lillemodel.com). A Lille Model score greater than 0.45, calculated after seven days of treatment with prednisolone, means failure to respond to treatment and predicts a six-month mortality of about 75% (Lefkowitz 2005).

Description of the intervention

Glucocorticosteroids are used as anti-inflammatory drugs. They are also known as glucocorticoids, corticosteroids, or steroids. Glucocorticosteroid agents mimic the endogenous glucocorticoid, cortisol (Rhen 2005). Glucocorticosteroids, primarily regulated by corticotropin, are considered to have anti-inflammatory effects as well as metabolic and immunogenic effects in the body, by blocking the infiltration of the white blood cells in the liver tissue. (Rhen 2005). It is agreed that the anti-inflammatory effect of glucocorticosteroids are mediated primarily through repression of gene transcription (Schäcke 2002).

How the intervention might work

Glucocorticosteroids administered to people with alcoholic hepatitis repair the liver injury by decreasing the liver polymorphonuclear neutrophils (effector cells) infiltrates and the level of pro-inflammatory mediators such as tumour necrosis factor-alpha, intercellular adhesion molecule 1, interleukin-6, and interleukin-8 in the liver tissue (Taïeb 2000; Spahr 2001). The benefits of

corticosteroids ensue from short-term vascular changes (Schäcke 2002). However, adverse events have still been poorly reported.

Why it is important to do this review

The benefits and harms of corticosteroids for people with alcoholic hepatitis have been studied extensively in a number of randomised clinical trials in order to determine the best route of administration, dose, and duration. However, results have been contradictory. So far, we have found six published meta-analyses with randomised clinical trials (Reynolds 1989; Imperiale 1990; Daures 1991; Christensen 1995; Rambaldi 2008; Mathurin 2011). The various conclusions regarding patient-oriented outcomes were explained by the review authors with differences in glucocorticosteroid regimens, trial quality, participants' characteristics, and clinical spectrum of the disease. Reynolds 1989 concluded that corticosteroid treatment could help only the most severely ill people with severe alcoholic hepatitis characterised by high levels of serum bilirubin, prolonged prothrombin times, and development of hepatic encephalopathy. Imperiale 1990 concluded that glucocorticosteroids reduced short-term mortality in people with severe alcoholic hepatitis provided that they also had hepatic encephalopathy but did not have severe gastrointestinal bleeding. Daures 1991 concluded that further randomised clinical trials were needed to confirm the benefits and harms of glucocorticosteroids, especially in people with severe alcoholic hepatitis. Christensen 1995 could not find sufficient proof supporting the routine use of glucocorticosteroids in people with alcoholic hepatitis, including people with hepatic encephalopathy. Rambaldi 2008 concluded that glucocorticosteroids did not improve overall survival in people with alcoholic hepatitis. Based on the Trial Sequential Analysis of the subgroup of people with Maddrey's score of at least 32 or spontaneous hepatic encephalopathy, the required information size of 2420 people for the outcome mortality was far from reached with only 249 participants randomised in the six randomised trials (Rambaldi 2008). Using the Lille model, Mathurin 2011 concluded that glucocorticosteroids significantly improved 28-day survival in people with severe alcoholic hepatitis. The Mathurin 2011 meta-analysis was based on individual data from five randomised clinical trials. This is why we decided to conduct this Cochrane systematic review in order to assess the efficacy of glucocorticosteroids in people with alcoholic hepatitis with or without complications.

OBJECTIVES

To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis.

METHODS

Criteria for considering studies for this review

Types of studies

We will include randomised clinical trials in which glucocorticosteroids have been assessed in people with alcoholic hepatitis, irrespective of year of publication or language. We will also include randomised clinical trials reported in an abstract form.

We will include quasi-randomised studies and observational studies identified during our searches for the assessment of harms.

Types of participants

We will include adults with alcoholic hepatitis, according to the diagnostic work-up used in the individual randomised clinical trial. We will consider alcoholic hepatitis as mild if randomised participants had jaundice for less than three months, Maddrey's score was 32 or less, bilirubin level was less than 50 $\mu\text{mol/L}$, and the person was an active drinker.

We will consider alcoholic hepatitis as severe at any stage of the alcoholic liver disease with the presence of spontaneous hepatic encephalopathy, or Maddrey's score higher than 32 (Maddrey's score = $4.6 \times$ prothrombin time (seconds) + serum bilirubin (milligrams per decilitre)) (Maddrey 1978). We will consider trials published before or after 1989 carefully, as the Maddrey's score was modified in 1989 in order to stratify severe alcoholic hepatitis and define the group of people to be treated.

Included trial participants diagnosed with severe alcoholic hepatitis may also manifest with hepatic encephalopathy, gastrointestinal bleeding, cirrhosis (e.g., classified with Child-Pugh score - Child-Pugh type C (Pugh 1973)), ascites, hepatorenal syndrome, hyponatraemia, and spontaneous bacterial peritonitis.

Types of interventions

Glucocorticosteroids administered by any route, dose, and duration versus placebo or no intervention.

We will allow co-interventions provided they do not differ between intervention and control groups.

Types of outcome measures

Primary outcomes

- All-cause mortality.
- Health-related quality of life (any valid continuous outcome scale as defined by the trial authors).

- Serious adverse events during treatment. We will use the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's definition of a serious adverse event (ICH-GCP 1997), that is, any untoward medical occurrence that results in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. We will consider all other adverse events as non-serious (see [Secondary outcomes](#)).

Secondary outcomes

- Alcohol liver-related mortality.
- Proportion of participants with one or more of the following complications: ascites, hepatorenal syndrome, spontaneous bacterial peritonitis, gastrointestinal bleeding, hepatic encephalopathy, non-obstructive jaundice, systemic inflammatory response syndrome, sepsis, or hepatocellular carcinoma.
- Proportion of people with non-serious adverse events according to type.

Exploratory outcomes

- Proportion of participants with an increase of liver enzymes as defined by the trialists.
- Proportion of participants with a decrease of prothrombin index as defined by the trialists.
- Proportion of participants with a decrease of serum albumin as defined by the trialists.

We plan to collect data at 'up to three months' follow-up' for all the outcomes, as it has been shown that survival of people with alcoholic hepatitis will mainly rely on their abstinence beyond that time point (see [Background](#)). In addition, glucocorticosteroids may have short-term effects. By making 'up to three months' our primary time point, we will be unlikely to be mixing outcomes such as deaths because of alcoholic hepatitis, because of cirrhosis, and because of recidivism of alcoholism. In addition, we will also assess the effects of glucocorticosteroids on maximal follow-up, but outcomes at this time point may be confounded ([Thursz 2015](#)).

Search methods for identification of studies

Electronic searches

We will search The Cochrane Hepato-Biliary Group Controlled Trials Register ([Gluud 2016](#)), Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OvidSP), EMBASE (OvidSP), Science Citation Index Expanded (Web of Science)

(Royle 2003), and LILACS (Castro 1997). We will apply no language or document type restrictions. Appendix 1 shows the preliminary search strategies with the expected time spans of the searches.

Searching other resources

We will identify additional references by handsearching the reference lists of articles from the computerised databases and relevant review articles.

We will search online trial registries such as clinicaltrials.gov, European Medicines Agency (www.ema.europa.eu), World Health Organization International Clinical Trial Registry Platform (www.who.int/ictrp), the Food and Drug Administration (www.fda.gov), and pharmaceutical company sources for ongoing or unpublished trials.

Data collection and analysis

We will follow the available guidelines provided in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011), and the Cochrane Hepato-Biliary Group Module (Gluud 2016). We will perform the analyses using Review Manager 5 (RevMan 2014) and Trial Sequential Analysis (Thorlund 2011; TSA 2011). We will assess the evidence according to Jakobsen and colleagues (Jakobsen 2014).

Selection of studies

We will retrieve publications that we consider to be potentially eligible for inclusion after reading their abstracts, and review articles that may provide useful references for studies. Three review authors (CP, DV, MT) will independently review publications for eligibility. They will assess each publication to determine if trial participants and the interventions administered meet the inclusion criteria. We will only include abstracts if sufficient data are provided for analysis. We will resolve disagreements by discussion or using any of the remaining authors for arbitration.

Data extraction and management

Three review authors (CP, DV, MT) will independently complete a data extraction form for all included studies. They will extract general information on the trial such as publication title; place and year of publication; trial design; inclusion and exclusion criteria; preliminary sample size calculation reached or not; number of participants randomised in each trial and following treatment allocation; diagnostic work-up; age (mean or median); sex or sex ratio; race; co-infection; type, dose, and route of administration of glucocorticosteroids and their possible link with adverse events; concurrent medications used; length of trial; and length of follow-

up. They will ensure that they have retrieved all possible data required for measuring the outcomes of this protocol. The authors will resolve disagreements by discussion or using any of the remaining authors for arbitration.

The three authors will also extract data on malnutrition, if malnutrition is clearly defined by the trial authors. We will use the extracted information for discussion only.

Assessment of risk of bias in included studies

Three review authors (CP, DV, MT) will independently assess the risk of bias of each included trial according to the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011), the Cochrane Hepato-Biliary Group Module (Gluud 2015), and methodological studies (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008; Lundh 2012; Savović 2012a; Savović 2012b). We will use the following definitions in the assessment of risk of bias.

Allocation sequence generation

- Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial.
- Unclear risk of bias: the method of sequence generation was not specified.
- High risk of bias: the sequence generation method was not random. We will include such studies only for assessments of harms.

Allocation concealment

- Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g., if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).
- Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.
- High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. We will include such studies only for assessments of harms.

Blinding of participants and personnel

- Low risk of bias: it was mentioned that both participants and personnel providing the interventions were blinded, and the method of blinding was described, so that knowledge of allocation was prevented during the trial.

- Unclear risk of bias: it was not mentioned if the trial was blinded, or the trial was described as blinded, but the method or extent of blinding was not described, so that knowledge of allocation was possible during the trial.
- High risk of bias: the trial was not blinded, so that the allocation was known during the trial.

Blinded outcome assessment

- Low risk of bias: it was mentioned that both participants and personnel providing the interventions were blinded, and the method of blinding was described, so that knowledge of allocation was prevented during the trial.
- Unclear risk of bias: it was not mentioned if the trial was blinded, or the trial was described as blinded, but the method or extent of blinding was not described, so that knowledge of allocation was possible during the trial.
- High risk of bias: the trial was not blinded, so that the allocation was known during the trial.

Incomplete outcome data

- Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data.
- Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.
- High risk of bias: the results were likely to be biased due to missing data.

Selective outcome reporting

- Low risk of bias: the trial reported the following pre-defined outcomes: all-cause mortality, serious adverse events, and alcohol liver-related mortality. If the original trial protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g., clinicaltrials.gov), the outcomes sought should have been those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes will not be considered to be reliable.
- Unclear risk of bias: not all pre-defined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.
- High risk of bias: one or more pre-defined outcomes were not reported.

For-profit bias

- Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design, conductance, or analyses of results of the trial.
- Unclear risk of bias: the trial may or may not be free of for-profit bias as no information on clinical trial support or sponsorship was provided.
- High risk of bias: the trial was sponsored by industry or received other type of for-profit support.

Other bias

- Low risk of bias: the trial appeared to be free of other bias domains (e.g. academic bias or authors had conducted trials on the same topic) that could put it at risk of bias.
- Unclear risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias.
- High risk of bias: there were other factors in the trial that could put it at risk of bias.

We will classify each trial as having a low, unclear, or high risk of bias based on the definitions described above. We will include a bias risk assessment combining all domains and categorise trials as low risk of bias if none of the domains are classed as high or unclear risk of bias. Moreover, we will consider trials with one or more domains with unclear or high risk of bias as trials with high risks of bias.

We will assess the domains 'Blinding of outcome assessment', 'Incomplete outcome data', and 'Selective outcome reporting' for each outcome result. Thus, we will be able to assess the bias risk for each outcome result in addition for each trial (overall risk of bias of each trial). We will base our primary conclusions on the outcome results of our primary outcomes with low risk of bias.

Measures of treatment effect

Dichotomous outcomes

We will use risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes.

Continuous outcomes

We will use mean difference (MD) with 95% CI for continuous outcomes. We will use the standardised mean difference (SMD) with 95% CI for continuous outcomes only if the included studies use different scales for quality of life.

Unit of analysis issues

The single participant, randomised in the trial.

Dealing with missing data

If dichotomous or continuous data are missing in a published report, we will, whenever possible, contact the original investigators to request the missing data.

If trialists used intention-to-treat analysis to deal with missing data, we will use these data in our primary analysis. If required data for intention-to-treat analysis are missing, we may not be able to perform such an analysis.

Dealing with missing data using sensitivity analysis

We will include missing data by considering participants as treatment failures or treatment successes by imputing them according to the following two scenarios:

- extreme-case analysis favouring the experimental intervention ('best-worst' case scenario): none of the participants who dropped out from the experimental group experienced the outcome, but all of the participants who dropped out from the control group experienced the outcome; including all randomised participants in the denominator.
- extreme-case analysis favouring the control ('worst-best' case scenario): all participants who dropped out from the experimental group, but none from the control group experienced the outcome; including all randomised participants in the denominator.

For continuous outcomes, in our case quality of life, we will perform a 'best-worst' case scenario analysis assuming that all participants lost to follow-up in the experimental group had an improved outcome (the group mean plus 1 standard deviation (SD)); and all participants with missing outcomes in the control group had a worsened outcome (the group mean minus 1 SD) (Jakobsen 2014). We will also perform a 'worst-best' case scenario analysis assuming that all participants lost to follow-up in the experimental group had a worsened outcome (the group mean minus 1 SD); and all participants with missing outcomes in the control group had an improved outcome (the group mean plus 1 SD) (Jakobsen 2014).

We will perform the two sensitivity scenario analyses only for our primary outcomes. We will present the results of both scenarios in our review.

Assessment of heterogeneity

We will address the presence of heterogeneity in both clinical and statistical ways.

We will assess heterogeneity by visual inspection of the forest plots. To assess heterogeneity between the trials formerly, we will specifically examine the degree of heterogeneity observed in the results using the I^2 statistic (Higgins 2002). As thresholds for the interpretation of the I^2 statistic can be misleading, we will use the following approximate guide for interpretation of heterogeneity

provided in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011):

- 0% to 40%: might not be important;
- 30% to 60%: may represent moderate heterogeneity*;
- 50% to 90%: may represent substantial heterogeneity*;
- 75% to 100%: considerable heterogeneity*.

*The importance of the observed value of the I^2 statistic depends on the magnitude and direction of effects and the strength of evidence for heterogeneity (e.g., P value from the Chi^2 test, or a CI for the I^2 statistic).

For the heterogeneity adjustment of the required information size in the Trial Sequential Analysis, we will use diversity (D^2) because the I^2 statistics used for this purpose consistently underestimate the required information size (Wetterslev 2009).

Depending on the number of eligible trials, we will add co-variables that may explain heterogeneity to a meta-regression model to adjust for heterogeneity.

Assessment of reporting biases

If we include 10 or more trials, we will draw funnel plots to assess reporting biases from the individual trials by plotting the RR on a logarithmic scale against its standard error (Egger 1997; Higgins 2011).

For dichotomous outcomes, we will test asymmetry using the Harbord test in cases where τ^2 is less than 0.1 (Harbord 2006), and we will use R ucker 2008 in cases where τ^2 is more than 0.1. For continuous outcomes, we will use the regression asymmetry test (Egger 1997), and the adjusted rank correlation (Begg 1994).

Data synthesis

Meta-analysis

We will perform the meta-analyses using Review Manager 5 (RevMan 2014), and according to the recommendations stated in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

We will present the results of dichotomous outcomes of individual trials as RR with 95% CI and the results of the continuous outcomes as MD with 95% CI.

Assessment of significance

We will perform the meta-analyses using Review Manager 5 (RevMan 2014). We will present the results of dichotomous outcomes of individual trials as RR with 95% CI and the results of the continuous outcomes as MD with 95% CI. We will apply both fixed-effect model (DeMets 1987) and random-effects model (DerSimonian 1986) meta-analyses. If there are statistically significant discrepancies in the results (e.g., one giving a significant

intervention effect and the other no significant intervention effect), we will report the more conservative point estimate of the two (Jakobsen 2014). The more conservative point estimate is the estimate closest to zero effect. If the two point estimates are equal, we will use the estimate with the widest CI as our main result of the two analyses. We will consider a P value of 0.025 or less, two-tailed, as statistically significant if the required information size is reached due to the three primary outcomes (Jakobsen 2014). We will use the eight-step procedure to assess if the thresholds for significance are crossed (Jakobsen 2014). We will present heterogeneity using the I^2 statistic (Higgins 2002). We will present the results of the individual trials and meta-analyses in the form of forest plots.

Where data are only available from one trial, we will use Fisher's exact test for dichotomous data (Fisher 1922), and Student's t-test for continuous data (Student 1908), to present the results in a narrative way.

Trial Sequential Analysis

We will apply Trial Sequential Analysis for both dichotomous and continuous outcomes (Thorlund 2011; TSA 2011), as cumulative meta-analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (Wetterslev 2008). To control random errors, we will calculate the diversity-adjusted required information size (DARIS) (i.e., the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) (Brok 2008; Wetterslev 2008; Brok 2009; Thorlund 2010).

In our meta-analysis, we will base the DARIS for dichotomous outcomes on the event proportion in the control group; assumption of a plausible relative risk reduction of 20% of the risk observed in the included trials with low risk of bias; a risk of type I error of 2.5% due to three primary outcomes (Jakobsen 2014), a risk of type II error of 20%, and the diversity of the included trials in the meta-analysis. For quality of life, we will estimate DARIS using a minimal relevant difference of 10% of the mean response observed in the control group; the SD; alpha of 2.5% due to the primary outcomes (Jakobsen 2014); beta of 20%; and the diversity as estimated from the trials in the meta-analysis (Wetterslev 2009). We will also calculate and report the Trial Sequential Analysis adjusted 95% CI (Thorlund 2011).

The underlying assumption of Trial Sequential Analysis is that testing for statistical significance may be performed each time a new trial is added to the meta-analysis. We will add the trials according to the year of publication, and, if more than one trial has been published in a year, we will add trials alphabetically according to the last name of the first author. On the basis of the DARIS, we will construct the trial sequential monitoring boundaries for benefit, harm, and futility (Wetterslev 2008; Thorlund 2011). These boundaries will determine the statistical inference one may draw regarding the cumulative meta-analysis that has not reached the

DARIS; if the trial sequential monitoring boundary for benefit or harm is crossed before the DARIS is reached, firm evidence may be established and further trials may be superfluous. However, if the boundaries are not crossed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. However, if the cumulative Z-curve crosses the trial sequential monitoring boundaries for futility, no more trials may be needed.

A more detailed description of Trial Sequential Analysis can be found at www.ctu.dk/tsa/ (Thorlund 2011).

Subgroup analysis and investigation of heterogeneity

Whenever possible, we will perform the following subgroup analyses.

- Trials with low risk of bias compared to trials with high risk of bias.
 - Trials with participants with mild alcoholic hepatitis compared to trials with severe alcoholic hepatitis, following the Maddrey's score of 32 or lower or higher than 32, or another score used.
 - Trials with dose of the glucocorticosteroid 40 mg or less compared to trials with dose of the glucocorticosteroid more than 40 mg.
 - Trials with people with severe hepatic hepatitis without cirrhosis compared to trials with people with severe alcoholic hepatitis with cirrhosis. If cirrhosis is classified by Child-Pugh score, then we may be able to perform additional subgroup analyses in order to adjust for the clinical spectrum of the disease.
 - Trials with people with severe alcoholic hepatitis without hepatorenal syndrome compared to trials with people with severe alcoholic hepatitis with hepatorenal syndrome.
 - Trials with people with severe alcoholic hepatitis without ascites compared to trials with people with severe alcoholic hepatitis with ascites.

Additional subgroup analyses maybe considered at the review stage. Due to the large number of subgroup analyses, we will interpret them conservatively.

Sensitivity analysis

To assess the robustness of the eligibility criteria, in addition to the sensitivity analyses specified under [Dealing with missing data](#), we will undertake sensitivity analyses that may explain our findings as well as any observed heterogeneity.

'Summary of findings' tables

We will create 'Summary of findings' tables on all review outcomes using GRADEpro (tech.cochrane.org/revman/other-resources/gradepr). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be

confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within-study risk of bias, indirectness of the evidence, heterogeneity of the data, imprecision of effect estimates (wide CIs and as evaluated with our Trial Sequential Analyses) (Jakobsen 2014), and risk of publication bias (Guyatt 2008; Balshem 2011; Guyatt 2011a; Guyatt 2011b; Guyatt 2011c; Guyatt 2011d; Guyatt 2011e; Guyatt 2011f; Guyatt 2011g; Guyatt 2011h; Guyatt 2013a; Guyatt 2013b; Guyatt 2013c; Mustafa 2013).

We will define the levels of evidence as 'high', 'moderate', 'low', or 'very low'. These grades are defined as follows.

- High certainty: this research provides a very good indication of the likely effect; the likelihood that the effect will be substantially different is low.
- Moderate certainty: this research provides a good indication of the likely effect; the likelihood that the effect will be substantially different is moderate.
- Low certainty: this research provides some indication of the likely effect; however, the likelihood that it will be substantially different is high.

- Very low certainty: this research does not provide a reliable indication of the likely effect; the likelihood that the effect will be substantially different is very high.

ACKNOWLEDGEMENTS

Peer reviewers: Richard Hu, USA; Sreeram Parupudi, USA.

Contact editors: Vanja Giljaca, Croatia; Janus Christian Jakobsen, Denmark.

Cochrane Review Group funding acknowledgement: the Danish State is the largest single funder of The Cochrane Hepato-Biliary Group through its investment in The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Denmark. Disclaimer: the views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the Danish State or The Copenhagen Trial Unit.

REFERENCES

Additional references

Balshem 2011

Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology* 2011; **64**(4):401–6. [PUBMED: 21208779]

Becker 1996

Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. *Hepatology (Baltimore, Md.)* 1996; **23**: 1025–9.

Beckett 1961

Beckett AG, Livingstone AV, Hill KR. Acute alcoholic hepatitis. *British Medical Journal* 1961; **2**:1113–9.

Begg 1994

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; **50**(4): 1088–101. [PUBMED: 7786990]

Brok 2008

Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. *Journal of Clinical Epidemiology* 2008; **61**:763–9.

Brok 2009

Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive -- trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently

conclusive neonatal meta-analyses. *International Journal of Epidemiology* 2009; **38**(1):287–98.

Carithers 1989

Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. *Annals of Internal Medicine* 1989; **110**:685–90. [MEDLINE: 1989191875]

Castro 1997

Castro AA, Clark OAC, Atallah A. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS). *Sao Paulo Medical Journal* 1997; **115**:1423–6. [MEDLINE: 1998194037]

Christensen 1995

Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables [see comments]. *Gut* 1995; **37**(1): 113–8. [MEDLINE: 1995402786]

Daures 1991

Daures JP, Peray P, Bories P, Blanc P, Yousfi A, Michel H, et al. Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis. *Gastroentérologie Clinique et Biologique* 1991; **15**(3):223–8.

DeMets 1987

DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. *Statistics in Medicine* 1987; **6**(3):341–50.

DerSimonian 1986

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986; **7**(3):177–88.

Dominguez 2008

Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. *American Journal of Gastroenterology* 2008;**103**:2747–56.

Dunn 2005

Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. *Hepatology* 2005;**41**: 353–8.

EASL 2012

European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. *Journal of Hepatology* 2012;**57**:399–420.

Egger 1997

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)* 1997;**315**(7109):629–34.

Ellis 2012

Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. *Journal of Hepatology* 2012;**56**(5):1171–80.

Fisher 1922

Fisher RA. On the interpretation of X^2 from contingency tables, and the calculation of P. *Journal of the Royal Statistical Society* 1922;**85**(1):87–94.

Forrest 2005

Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. *Gut* 2005;**54**:1174–9.

Gerber 1973

Gerber MA, Orr W, Denk H, Schaffner F, Popper H. Hepatocellular hyalin in cholestasis and cirrhosis: its diagnostic significance. *Gastroenterology* 1973;**64**(1):89–98.

Gluud 2016

Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 4. Art. No.: LIVER.

Guyatt 2008

Guyatt G, Oxman AD, Vist GE, Kunz R, Falck Y, Alonso CP, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ (Clinical Research Ed.)* 2008;**336**(7650):924–6.

Guyatt 2011a

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction -- GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology* 2011;**64**(4):383–94. [PUBMED: 21195583]

Guyatt 2011b

Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *Journal of Clinical Epidemiology* 2011;**64**(4):395–400. [PUBMED: 21194891]

Guyatt 2011c

Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence -- study limitations (risk of bias). *Journal of Clinical Epidemiology* 2011;**64**(4):407–15. [PUBMED: 21247734]

Guyatt 2011d

Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence -- publication bias. *Journal of Clinical Epidemiology* 2011;**64**(12):1277–82. [PUBMED: 21802904]

Guyatt 2011e

Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence -- imprecision. *Journal of Clinical Epidemiology* 2011;**64**(12):1283–93. [PUBMED: 21839614]

Guyatt 2011f

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence -- inconsistency. *Journal of Clinical Epidemiology* 2011;**64**(12):1294–302. [PUBMED: 21803546]

Guyatt 2011g

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence -- indirectness. *Journal of Clinical Epidemiology* 2011;**64**(12):1303–10. [PUBMED: 21802903]

Guyatt 2011h

Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. *Journal of Clinical Epidemiology* 2011;**64**(12):1311–6. [PUBMED: 21802902]

Guyatt 2013a

Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *Journal of Clinical Epidemiology* 2013;**66**(2):151–7. [PUBMED: 22542023]

Guyatt 2013b

Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. *Journal of Clinical Epidemiology* 2013;**66**(2):158–72. [PUBMED: 22609141]

Guyatt 2013c

Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. *Journal of Clinical Epidemiology* 2013;**66**(2): 173–83. [PUBMED: 23116689]

Harbord 2006

Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Statistics in Medicine* 2006;**25**(20): 3443–57.

Higgins 2002

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**(11):1539–58.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

ICH-GCP 1997

International Conference on Harmonisation Expert Working Group. *International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines*. Vol. 1, Philadelphia: Barnett International/PAREXEL, 1997.

Imperiale 1990

Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. *Annals of Internal Medicine* 1990;**113**(4):299–307.

Jakobsen 2014

Jakobsen J, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Medical Research Methodology* 2014;**14**:120.

Jensen 1994

Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey). *Hepatology* 1994;**20**:1061–77. [MEDLINE: 1995012083]

Kjaergard 2001

Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Annals of Internal Medicine* 2001;**135**(11):982–9.

Lefkowitz 2005

Lefkowitz JH. Morphology of alcoholic liver disease. *Clinics in Liver Disease* 2005;**9**(1):37–53.

Lieber 1999

Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. *Journal of Hepatology* 1999;**30**:1155–9.

Louvet 2007

Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology (Baltimore, Md.)* 2007;**45**(6):1348–54.

Lundh 2012

Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews* 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]

Maddrey 1978

Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. *Gastroenterology* 1978;**75**:193–9.

Mathurin 2011

Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. *Gut* 2011;**60**(2):255–60.

Mendenhall 1984

Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. *New England Journal of Medicine* 1984;**311**:1464–70.

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet* 1998;**352**(9128):609–13.

Mustafa 2013

Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. *Journal of Clinical Epidemiology* 2013;**66**(7):736–42; quiz 742.e1–5. [PUBMED: 23623694]

Petrasek 2013

Petrasek J, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. *Proceedings of the National Academy of Sciences of the United States of America* 2013;**110**(41):16544–9.

Phillips 2006

Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial. *Journal of Hepatology* 2006;**44**:784–90.

Pugh 1973

Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *British Journal of Surgery* 1973;**60**:646–9.

Rambaldi 2008

Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis - a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. *Alimentary Pharmacology & Therapeutics* 2008;**27**(12):1167–78.

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Reynolds 1989

Reynolds TB, Benhamou J-P, Blake J, Naccarato R, Orrego H. Treatment of acute alcoholic hepatitis. *Gastroenterology International* 1989;**2**(4):208–16.

Rhen 2005

Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. *New England Journal of Medicine* 2005;**353**(16):1711–23.

Royle 2003

Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. *International Journal of Technology Assessment in Health Care* 2003;**19**(4):591–603.

Rücker 2008

Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses with binary outcomes. *Statistics in Medicine* 2008;**27**:746–63.

Savović 2012a

Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Health Technology Assessment* 2012;**16**(35):1–82.

Savović 2012b

Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Annals of Internal Medicine* 2012;**157**(6):429–38.

Schulz 1995

Schulz KF, Chalmers I, Hayes R, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment in controlled trials. *JAMA* 1995;**273**:408–12. [MEDLINE: 1995123716]

Schäcke 2002

Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. *Pharmacology & Therapeutics* 2002;**96**(1):23–43.

Spahr 2001

Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. *Journal of Hepatology* 2001;**35**(5):582–9.

Stickel 2013

Stickel F, Seitz HK. Update on the management of alcoholic steatohepatitis. *Journal of Gastrointestinal Liver Disease* 2013;**22**(2):189–97.

Student 1908

Student. The probable error of a mean. *Biometrika* 1908;**6**(1):1–25.

Taïeb 2000

Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. *Journal of Hepatology* 2000;**32**(4):579–86.

Thorlund 2010

Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using

isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. *Clinical Epidemiology* 2010;**2**:57–66.

Thorlund 2011

Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 7 June 2016).

Thursz 2015

Thursz M, Forrest E, Roderick P, Day C, Austin A, O' Grady J, et al. The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. *Health Technology Assessment* 2015; Vol. 19, issue 102: 1–105.

TSA 2011 [Computer program]

Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.

Wetterslev 2008

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *Journal of Clinical Epidemiology* 2008;**61**(1):64–75.

Wetterslev 2009

Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in a random-effects meta-analysis. *BMC Medical Research Methodology* 2009;**9**:86.

WHO 2010

World Health Organization. Global strategy to reduce the harmful use of alcohol, 2010. www.who.int/substance_abuse/msbalcstrategy.pdf (accessed 7 June 2016).

WHO 2013

Sauced RS. Update on background paper 6.14. Harmful use of alcohol, alcohol use, disorders, and alcoholic liver diseases, 2013. www.who.int/medicines/areas/priority_medicines/BP6_14Alcohol.pdf (accessed 7 June 2016).

Wood 2008

Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ (Clinical Research Ed.)* 2008;**336**:601–5.

Wu 1999

Wu D, Cederbaum AI. Ethanol-induced apoptosis to stable HepG2 cell lines expressing human cytochrome P-4502E1. *Alcoholism, Clinical and Experimental Research* 1999;**23**: 67–76.

References to other published versions of this review**Saconato 1999**

Saconato H, Gluud C, Christensen E, Atallah AN. Glucocorticosteroids for alcoholic hepatitis. *Cochrane*

APPENDICES

Appendix I. Search strategies

Database	Search performed	Search strategy
Cochrane Hepato-Biliary Controlled Trials Register	At the review stage.	(glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*) AND (alcohol* and (liver or hepati*))
Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley)	At the review stage.	#1 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees #2 (glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*) #3 #1 or #2 #4 MeSH descriptor: [Hepatitis, Alcoholic] explode all trees #5 (alcohol* and (liver or hepati*)) #6 #4 or #5 #7 #3 and #6
MEDLINE (OvidSP)	At the review stage.	1. exp Adrenal Cortex Hormones/ 2. (glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 3. 1 or 2 4. exp Hepatitis, Alcoholic/ 5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 6. 4 or 5 7. 3 and 6 8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 9. 7 and 8

(Continued)

EMBASE (OvidSP)	At the review stage.	1. exp corticosteroid/ 2. (glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 3. 1 or 2 4. exp alcohol liver disease/ 5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 6. 4 or 5 7. 3 and 6 8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 9. 7 and 8
Science Citation Index Expanded (Web of Science)	At the review stage.	#5 #4 AND #3 #4 TS=(random* or blind* or placebo* or meta-analys*) #3 #2 AND #1 #2 TS=(alcohol* and (liver or hepati*)) #1 TS=(glucocortico* or steroid* or dexamethasone or prednis* or hydrocortisone or corticosteroid* or cortiso* or budesonide* or beclomethasone*)

WHAT'S NEW

Last assessed as up-to-date: 9 June 2016.

Date	Event	Description
9 June 2016	New citation required and major changes	This protocol is a major update of a withdrawn review protocol by Saconato et al (Saconato 1999)

CONTRIBUTIONS OF AUTHORS

Chavdar Pavlov (CP) and Giovanni Casazza (GC): drafted the protocol.

Dimitrinka Nikolova (DN): revised the protocol.

Edvard Volcek (EV), Emmanuel Tsochatzis (ET), and Christian Glud (CG) commented on the protocol.

All authors addressed comments by peer reviewers and editors, reviewed the final version of the protocol, and approved its validity for publication.

Daria Varganova (DV) from Russia will join the authors' team at the review stage.

DECLARATIONS OF INTEREST

The authors of this protocol declare no financial, academic, or personal conflicts of interest.

SOURCES OF SUPPORT

Internal sources

- The Cochrane Hepato-Biliary Group Editorial Team Office, Denmark.

External sources

- No sources of support supplied

NOTES

Cochrane Reviews can be expected to have a high percentage of overlap in the methods section because of standardised methods. In addition, overlap may be observed across two of our protocols as they share at least four common authors.